Immuneering (IMRX) Change in Receivables (2020 - 2023)
Historic Change in Receivables for Immuneering (IMRX) over the last 4 years, with Q2 2023 value amounting to -$1046.0.
- Immuneering's Change in Receivables rose 9896.63% to -$1046.0 in Q2 2023 from the same period last year, while for Mar 2024 it was -$1046.0, marking a year-over-year increase of 9962.45%. This contributed to the annual value of -$12417.0 for FY2023, which is 9468.5% up from last year.
- Latest data reveals that Immuneering reported Change in Receivables of -$1046.0 as of Q2 2023, which was up 9896.63% from -$11371.0 recorded in Q1 2023.
- Over the past 5 years, Immuneering's Change in Receivables peaked at $278185.0 during Q3 2020, and registered a low of -$250978.0 during Q4 2021.
- Moreover, its 4-year median value for Change in Receivables was -$17550.5 (2021), whereas its average is -$27133.6.
- The largest annual percentage gain for Immuneering's Change in Receivables in the last 5 years was 53573.0% (2022), contrasted with its biggest fall of 384770.37% (2022).
- Immuneering's Change in Receivables (Quarter) stood at -$78035.0 in 2020, then crashed by 221.62% to -$250978.0 in 2021, then skyrocketed by 76.98% to -$57763.0 in 2022, then soared by 98.19% to -$1046.0 in 2023.
- Its last three reported values are -$1046.0 in Q2 2023, -$11371.0 for Q1 2023, and -$57763.0 during Q4 2022.